Arcutis Biotherapeutics is exploding higher today, reaching a new 52-week high of $32.89. While the broader biotechnology sector remains active with various regulatory updates and clinical trial developments, there are no company-specific catalysts or filings released since October 16 that explain this move. Consequently, the stock appears to be benefiting from positive momentum within the biotech industry as investors react to a flurry of recent FDA approvals and clinical data presentations across the sector.